Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex fair value estimate is US$32.91 Vertex's US$19.50 ...

Switzerland-based CRISPR Therapeutics (CRSP) and Boston, Massachusetts-based Vertex (VRTX) have been collaborating together since signing an initial agreement in 2015, with Vertex paying CRISPR $75m ...

Vertex Flooring introduces distinctive marquetry flooring crafted with expert precision, offering custom wood designs ...

Google announced today that its generative AI support in Vertex AI, the company’s machine learning platform, is now generally available. Based on Google’s models like PaLM 2, Imagen and Codey, Vertex ...